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T he significant reduction in mortality after adminis- 
tration of intravenous streptokinase noted in a multi- 
center Italian trial (GISSI)l in more than 11,000 pa- 
tients in conjunction with similar trends from pooled, 
randomized studies in more than 10,000 patients2 
marked the beginning of the “reperfusion era.” In- 
travenous thrombolytic therapy when administered 
within the first 4 to 6 hours of acute myocardial infarc- 
tion (AMI) appears effective and is likely to become 
standard practice, whether with streptokinase, uro- 
kinase, tissue plasminogen activator or other throm- 
bolytic agents under investigation. Intracoronary 
streptokinase therapy, although effective in causing 
thrombolysis in up to 80% of patients, compared with 
the 30 to 60% rate found with intravenous streptoki- 
nase, has not been convincingly shown to significantly 
reduce mortality.2 The apparent failure of intracoro- 
nary streptokinase to significantly reduce mortality 
and improve ventricular function may in part be due to 
the delay in time of administration necessitated by 
angiography and in part by the limited number of pa- 
tients studied to reach statistical significance. Regard- 
less, the proved efficacy of intravenous thrombolytic 
therapy reduces the need for intracoronary thrombo- 
lysis in view of the effort and cost associated with 
intracoronary administration. 
Although intravenous tissued plasminogen activa- 
tor appears to be more effective than intravenous 
streptokinase in causing thrombolysis3+4 and can 
achieve successful reperfusion in 70 to 80% of patients 
if administered within the first few hours of onset of 
symptoms, it has a limitation in common with strepto- 
kinase in that at best it can only lyse the thrombus but 
cannot relieve the underlying residual stenosis. The 
underlying residual stenosis predisposes to recurrent 
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thrombosis, resulting in a relatively high incidence of 
reocclusion and subsequent ischemic events5 In fact, 
intravenous thrombolytic therapy does not appear to 
completely lyse the thrombus, as evidenced by recent 
angiographic studies.‘j 
A recent random study comparing the effects of 
intracoronary streptokinase to percutaneous trans- 
luminal coronary angioplasty (PTCA) suggests that 
PTCA will have an important role in the therapy of 
AMI. Although both intracoronary streptokinase and 
PTCA resulted in an almost identical reperfusion rate 
of approximately 85%, PTCA was more effective in 
improving global and regional ventricular function, 
reducing the frequency of postinfarction angina, exer- 
cise-induced ischemia before hospital discharge, and 
reocclusion. The improvement in global left ventricu- 
lar ejection fraction with PTCA in patients during 
AMI, first noted by Hartzler et al,* is thus confirmed. 
The significantly greater improvement in global and 
regional ventricular function with PTCA compared 
with intracoronary streptokinase therapy despite a 
similar thrombolytic rate is a result of relief of the 
underlying residual stenosis. Subsequent studies in 
patients with AM1 also have suggested that the degree 
of residual stenosis in the infarct-related artery deter- 
mines the degree of the immediate improvement in 
coronary blood flow.g The improvement in coronary 
blood flow resulting from a reduction in the degree of 
residual stenosis is directly correlated with improve- 
ment in global and regional myocardial function be- 
fore hospital discharge.g There is also a significant re- 
lation between time of reperfusion from onset of 
symptoms and subsequent improvement in ventricu- 
lar function.g-*l Thus, from our own and other studies 
it would appear that both the time to reperfusion and 
the degree of residual stenosis in the infarct-related 
artery appear critical for any reperfusion strategy. 
PTCA appears especially promising in patients 
with severe left ventricular dysfunction or cardiogenic 
shock. Initial pilot studies in patients with cardiogenic 
shock suggest that the mortality rate of cardiogenic 
shock is reduced compared with the previous reported 
experience with inotropic therapy and intravenous 
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thrombolytic therapy. l2 Although PTCA alone has 
been shown effective in improving both global and 
regional ventricular function and recurrent ischemic 
events, it is unlikely to be the strategy of choice be- 
cause of the time delay necessitated by the need for 
angiography and PTCA. Thus, sequential intravenous 
thrombolytic therapy followed by PTCA has been ex- 
plored13J4 and is undergoing evaluation in several 
prospective randomized trials. 
Although still relatively early, the role of PTCA in 
the therapy of AM1 is beginning to emerge. The results 
of the Thrombolysis in AM1 trial (TAMI)15 suggest that 
in patients in whom reperfusion is successful after 
intravenous tPA but who have a significant residual 
stenosis (more than 50% diameter narrowing), emer- 
gent PTCA may not be necessary. The strategy of 
emergent PTCA for all patients with a significant- 
ly narrowed infarct-related artery after successful 
thrombolysis results in use of the procedure in many 
patients with critical stenoses within the early hours of 
reperfusion who on follow-up 7 days later do not have 
a critical stenosis due to further clot lysis. Furthermore, 
the benefits from emergent PTCA as indicated by an 
improvement in ventricular function, decrease in the 
rate of reocclusion and ischemic events do not appear 
to be significantly different from those in the group in 
whom PTCA is performed electively or as needed on 
the basis of a spontaneous recurrence of symptoms or 
the occurrence of exercise induced ischemia. 
Whether performed emergently or electively, 
PTCA is likely to be an important component of any 
reperfusion strategy. Once intravenous thrombolysis is 
initiated and myocardial salvage achieved, patients 
may be at increased risk for early recurrent ischemia 
and or reocclusion. Patients in whom intravenous 
thrombolysis is successful should optimally be ob- 
served in a center with the capability for PTCA and or 
coronary artery bypass graft surgery, because recur- 
rent ischemia or reocclusion may occur within the ear- 
ly hours after intravenous thrombolysis. Unless the 
incidence of recurrent ischemia and reocclusion can 
be reduced after successful intravenous thrombolysis, 
we must consider further changes in our health care 
system, such as the emergency helicopter system de- 
veloped at the University of Michigan16 and the re- 
gionalization of health care for patients with AMI. If 
PTCA is performed in a patient with successful intra- 
venous thrombolysis it should be done with surgical 
standby. Reclosure or dissection of a recanalized ar- 
tery may result in recurrent symptoms and hemody- 
namic compromise, which can be corrected by prompt 
surgical revascularization. Coronary artery bypass 
graft surgery for complications of emergent PTCA can 
be accomplished with relatively low risk.17 
While PTCA and bypass surgery appear effective 
in relieving ischemia and preventing reinfarction in 
patients with recurrent ischemia or reocclusion after 
successful intravenous thrombolysis, it is not without 
risk. Its role in the elderly and those with a small, 
uncomplicated transmural AM1 must await the results 
of ongoing prospective randomized trials. Any signifi- 
cant mortality risk resulting from urgent angiography 
or PTCA would negate this strategy in low-risk pa- 
tients in whom the initial in-hospital and l-year mor- 
tality rate is low. 
The role of PTCA in the 20 to 30% of patients who 
fail initial intravenous thrombolysis remains uncer- 
tain. Early studies suggest that emergent PTCA is suc- 
cessful in achieving reperfusion in more than 90% of 
these patients and that reperfusion is accompanied by 
significant improvement in regional and global left 
ventricular function.l* Experience from the recent 
TAM1 trial suggests, however, that the success rate of 
emergent PTCA in this group may be somewhat less 
than 90% and the early reocclusion rate high, about 
25% .lg While the potential benefits of emergent PTCA 
in this group are great, so are the risks. Should further 
studies suggest a need for emergent PTCA in patients 
in whom intravenous thrombolysis fails, we must de- 
velop more effective noninvasive means of identifying 
patients in whom thrombolysis fails for triage to cen- 
ters with the capability of PTCA or coronary artery 
bypass graft surgery. Alternatively, we must develop 
more effective intravenous thrombolytic strategies that 
could open more than 90% of occluded infarct-related 
arteries, thereby reducing or eliminating the need for 
early angiography and emergent PTCA. 
Of concern is the added cost of reperfusion if PTCA 
or coronary artery bypass graft surgery either acutely 
or electively is found to be essential in a large percent- 
age of patients for optimal reduction in mortality after 
intravenous thrombolysis. Clearly, for this expendi- 
ture to be justified, we will need to have evidence that 
the cost/benefit ratio for this strategy is favorable. Ear- 
ly studies suggest that intravenous thrombolysis and 
PTCA may allow selection of patients for early hospi- 
tal discharge with the potential of a saving in net cost. 
Although we are optimistic that sequential intravenous 
thrombolysis followed by PTCA will prove effective in 
high-risk subsets of patients with acute infarction and 
those with recurrent ischemia and that the expense 
will be justified we have the obligation to proceed 
cautiously and await the results of ongoing random- 
ized trials in more patients before generalizing results 
of initial studies to all patients with AMI. 
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